Literature DB >> 23313749

Involvement of IL-1 and oncostatin M in acanthosis associated with hypertensive leg ulcer.

Jean-Philippe Giot1, Isabelle Paris, Pierre Levillain, Vincent Huguier, Sandrine Charreau, Adrianna Delwail, Martine Garcia, Julien Garnier, François-Xavier Bernard, Guy Dagregorio, Gérard Guillet, Franck Morel, Jean-Claude Lecron, Laure Favot.   

Abstract

Hypertensive leg ulcer (HLU) is an inflammatory disease characterized by intense pain, alteration of vascularization, and skin necrosis. The optimal treatment relies on surgical removal of necrotic tissues covered by a split-skin graft. We studied the histomorphology of the lesions and investigated the involvement of inflammatory cells and cytokines to further define the physiopathology of HLU. We report epidermis acanthosis and a preferential occlusion of the precapillary arterioles with infiltration of neutrophils, macrophages, and T lymphocytes in the dermis. OSM, IL-1β, and IL-6 were overexpressed in the ulcer, whereas the Th17-derived cytokines were not. In vitro, the addition of IL-1β and OSM promoted acanthosis and destructuring of reconstructed epidermis. Exogenous IL-1β and OSM synergistically induced epidermal acanthosis in mice. These data show that OSM and IL-1β are not only a biological characteristic signature of HLU, but these cytokines reflect a specific inflammatory state, directly involved in the pathogenesis. We suggest that anti-cytokine biotherapies could be an alternative strategy to surgery to treat HLU.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313749     DOI: 10.1016/j.ajpath.2012.11.030

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

1.  Oncostatin M reduces lesion size and promotes functional recovery and neurite outgrowth after spinal cord injury.

Authors:  Helena Slaets; Sofie Nelissen; Kris Janssens; Pia M Vidal; Evi Lemmens; Piet Stinissen; Sven Hendrix; Niels Hellings
Journal:  Mol Neurobiol       Date:  2014-07-05       Impact factor: 5.590

2.  Oncostatin M Counteracts the Fibrotic Effects of TGF-β1 and IL-4 on Nasal-Polyp-Derived Fibroblasts: A Control of Fibrosis in Chronic Rhinosinusitis with Nasal Polyps?

Authors:  Florent Carsuzaa; Émilie Béquignon; Matthieu Bainaud; Jean-François Jégou; Xavier Dufour; Jean-Claude Lecron; Laure Favot
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

Review 3.  The enigmatic cytokine oncostatin m and roles in disease.

Authors:  Carl D Richards
Journal:  ISRN Inflamm       Date:  2013-12-08

4.  Oncostatin M exerts a protective effect against excessive scarring by counteracting the inductive effect of TGFβ1 on fibrosis markers.

Authors:  Vincent Huguier; Jean-Philippe Giot; Marie Simonneau; Pierre Levillain; Sandrine Charreau; Martine Garcia; Jean-François Jégou; Charles Bodet; Franck Morel; Jean-Claude Lecron; Laure Favot
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

5.  Use of Cytokine Mix-, Imiquimod-, and Serum-Induced Monoculture and Lipopolysaccharide- and Interferon Gamma-Treated Co-Culture to Establish In Vitro Psoriasis-like Inflammation Models.

Authors:  Katarzyna Bocheńska; Marta Moskot; Magdalena Gabig-Cimińska
Journal:  Cells       Date:  2021-11-02       Impact factor: 6.600

6.  A metatranscriptomic approach to explore longitudinal tissue specimens from non-healing diabetes related foot ulcers.

Authors:  Michael Radzieta; Timothy J Peters; Hugh G Dickson; Allison J Cowin; Lawrence A Lavery; Saskia Schwarzer; Tara Roberts; Slade O Jensen; Matthew Malone
Journal:  APMIS       Date:  2022-05-10       Impact factor: 3.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.